J. Mintzer

L. Schneider, M. Weiner, J. Mintzer, 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial.

J. Olin, J. Mintzer, A. Porsteinsson, 2008, Current Alzheimer research.

Managing Behavioral Dyscontrol Related to Dementia

J. Mintzer, 2003 .

Agitation as a possible expression of generalized anxiety disorder in demented elderly patients: toward a treatment approach.

J. Mintzer, O. Brawman‐Mintzer, 1996, The Journal of clinical psychiatry.

Spinal cord injury: how can we improve the classification and quantification of its severity and prognosis?

J. Guest, J. Mintzer, M. Kindy, 2014, Journal of neurotrauma.

Induction of salivary nerve growth factor by Yogic breathing: a randomized controlled trial

J. Mintzer, A. Wahlquist, S. Balasubramanian, 2014, International Psychogeriatrics.

All purulence is local – epidemiology and management of skin and soft tissue infections in three urban emergency departments

J. Mintzer, C. Merritt, R. Merchant, 2013, BMC Emergency Medicine.

Risperidone in the management of psychiatric and neurodegenerative disease in the elderly: an update.

J. Mintzer, C. DeVane, 2003, Psychopharmacology bulletin.

The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory

Sterling C. Johnson, Keith A. Johnson, Joanne L. Lord, 2019, Nature Communications.

Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease.

R. Raman, N. Herrmann, J. Mintzer, 2016, Journal of Alzheimer's disease : JAD.

18F-florbetapir Positron Emission Tomography–determined Cerebral &bgr;-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery

David T. Jones, Keith A. Johnson, Jeffrey N. Browndyke, 2018, Anesthesiology.

Atypical antipsychotics in dementia

J. Mintzer, L. Blake, 2005 .

A Freedom Magazines Publication Supplement to Clinical Geriatrics and Annals of Long-Term Care

J. Mintzer, J. Streim, J. M. Ryan, 2006 .

FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease

Sterling C. Johnson, David T. Jones, Keith A. Johnson, 2020, Nature Communications.

A predictive model using the mesoscopic architecture of the living brain to detect Alzheimer’s disease

Sterling C. Johnson, Keith A. Johnson, Raymond Scott Turner, 2022, Communications Medicine.

Comprehensive analysis of epigenetic clocks reveals associations between disproportionate biological ageing and hippocampal volume

Sterling C. Johnson, Keith A. Johnson, Raymond Scott Turner, 2022, GeroScience.

Commentary: “Ceramide and cholesterol: Possible connections between normal aging of the brain and Alzheimer’s disease. Just hypotheses or molecular pathways to be identified?” by Claudio Costantini, Rekha M.K. Kolasani, Luigi Puglielli

A. Granholm, J. Mintzer, D. Bachman, 2005, Alzheimer's & Dementia.

Is sertraline treatment or depression remission in depressed Alzheimer’s patients associated with improved caregiver wellbeing? The Depression in Alzheimer’s Disease Study 2 (DIADS-2)

L. Schneider, P. Rabins, C. Meinert, 2014 .

Industry Satellite Symposia

J. Mintzer, G. Wilcock, M. Takeda, 2007, International Psychogeriatrics.

Identifying persons with dementia by use of a caregiver telephone interview.

J. Mintzer, P. Nietert, K. Costa, 1998, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Effectivenessof a Continuumof Care UsingBriefand PartialHospitalization forAgitatedDementia Patients

J. Mintzer, M. Saladin, D. Bachman, 1997 .

Apolipoprotein E and Gray Matter Volume Loss in Patients with Mild Cognitive Impairment

Z. Rumboldt, J. Mintzer, M. Spampinato, 2011 .

Hyperkalemia in Elderly Patients Receiving Standard Doses of Trimethoprim-Sulfamethoxazole

J. Mintzer, L. Pennypacker, J. Pitner, 1994, Annals of Internal Medicine.

An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease

Sterling C. Johnson, Keith A. Johnson, Raymond Scott Turner, 2022, Nature Aging.

The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure

J. Mintzer, P. Kershaw, 2003, International journal of geriatric psychiatry.

Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force.

C. Lyketsos, M. Carrillo, M. Sano, 2018, The journal of prevention of Alzheimer's disease.

Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease.

J. Mintzer, 2001, The Journal of clinical psychiatry.

Dementia with Lewy bodies

B. Dubois, I. McKeith, J. O'Brien, 2004, The Lancet Neurology.

Hexanucleotide repeat expansions in C9ORF72 in the spectrum of motor neuron diseases

Sterling C. Johnson, Nick C Fox, Keith A. Johnson, 2012, Neurology.

Cholesterol and Alzheimer's disease: clinical and experimental models suggest interactions of different genetic, dietary and environmental risk factors.

N. Greig, A. Granholm, J. Mintzer, 2004, Current drug targets.

Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits

Norbert Schuff, Michael W. Weiner, Robert C. Green, 2016, Scientific Reports.

MEASURING APATHY IN ALZHEIMER'S DISEASE IN THE APATHY IN DEMENTIA METHYLPHENIDATE TRIAL 2 (ADMET 2): A COMPARISON OF INSTRUMENTS

A. Levey, N. Herrmann, W. Burke, 2017, Alzheimer's & Dementia.

Sertraline for the Treatment of Depression in Alzheimer Disease: Genetic Influences

L. Schneider, C. Lyketsos, P. Rabins, 2011, Journal of geriatric psychiatry and neurology.

Clinical application of operationalized criteria for ‘Depression of Alzheimer's Disease’

L. Schneider, C. Lyketsos, I. Katz, 2005, International journal of geriatric psychiatry.

Designing a trial to evaluate potential treatments for apathy in dementia: The Apathy in Dementia Methylphenidate Trial (ADMET): The Apathy in Dementia Methylphenidate Trial (ADMET)

N. Herrmann, J. Mintzer, K. Lanctôt, 2012 .

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer’s disease

Nick C Fox, Keith A. Johnson, Raymond Scott Turner, 2022, Nature Communications.

GETTING DONEPEZIL INTO THE NURSING HOME ‐ Response to the Editor

P. Tariot, I. Katz, J. Cummings, 2003 .

The growing, ethnically diverse aging population: is our field advancing with it?

J. Mintzer, W. Faison, 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Anxiety in the Behavioral and Psychological Symptoms of Dementia

J. Mintzer, O. Brawman‐Mintzer, D. Mirski, 2000, International Psychogeriatrics.

Association of common genetic variants in GPCPD1 with scaling of visual cortical surface area in humans

Norbert Schuff, Adrian Preda, John Kornak, 2012, Proceedings of the National Academy of Sciences.

Efficacy and adverse effects of clozapine in four elderly psychotic patients.

J. Mintzer, C. Jackson, L. Pennypacker, 1995, The Journal of clinical psychiatry.

Caregiving for Hispanic Alzheimer's disease patients: understanding the problem.

J. Mintzer, M. Rubert, K. Herman, 1994, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future

Jeroen Aerssens, Mary Sano, Ravi Anand, 2007, International Psychogeriatrics.

Correlation between Alzheimer’s disease and type 2 diabetes using non-negative matrix factorization

Keith A. Johnson, Raymond Scott Turner, Joanne L. Lord, 2021, Scientific Reports.

Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau

Sterling C. Johnson, Nick C Fox, John X. Morris, 2020, Brain communications.

The impact of PICALM genetic variations on reserve capacity of posterior cingulate in AD continuum

Sterling C. Johnson, Keith A. Johnson, Joanne L. Lord, 2016, Scientific Reports.

Effect of CR1 Genetic Variants on Cerebrospinal Fluid and Neuroimaging Biomarkers in Healthy, Mild Cognitive Impairment and Alzheimer's Disease Cohorts

Keith A. Johnson, Joanne L. Lord, Colleen S. Albers, 2016, Molecular Neurobiology.

Rivastigmine Transdermal Patch Treatment for Moderate to Severe Cognitive Impairment in Veterans with Traumatic Brain Injury (RiVET Study): A Randomized Clinical Trial.

Philip D. Harvey, D. Reda, D. Arciniegas, 2021, Journal of neurotrauma.

Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

J. Mintzer, K. Rockwood, D. Wilkinson, 2001, Journal of neurology, neurosurgery, and psychiatry.

Diagnostic criteria for apathy in neurocognitive disorders

David S. Miller, Corinne E. Fischer, V. Manera, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Anticholinergic side-effects of drugs in elderly people

J. Mintzer, A. Burns, 2000, Journal of the Royal Society of Medicine.

Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial

David M. Shade, L. Schneider, C. Lyketsos, 2019, Alzheimer's & Dementia.

Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.

Pierre N Tariot, Paul Shin, Charles S Davis, 2015, JAMA.

Effect of Methylphenidate on Apathy in Patients With Alzheimer Disease: The ADMET 2 Randomized Clinical Trial.

David M. Shade, A. Levey, N. Herrmann, 2021, JAMA neurology.

Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer’s pathology

Sterling C. Johnson, David T. Jones, Taylor W. Schmitz, 2016, Nature Communications.

Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial.

G. Schellenberg, P. Peduzzi, J. McCarten, 2014, JAMA.

A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer’s disease patients with agitation

David M. Shade, J. Yesavage, L. Schneider, 2015, Journal of Pharmacokinetics and Pharmacodynamics.

Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE

Keith A. Johnson, Scott Ayton, Joanne L. Lord, 2015, Nature Communications.

Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways

Keith A. Johnson, Raymond Scott Turner, Sherye A. Sirrel, 2016, Scientific Reports.

Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease

Sterling C. Johnson, Christine L. Tardif, John X. Morris, 2021, Nature Communications.

A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease

James B. Brewer, Raymond Scott Turner, Paul S. Aisen, 2015, Neurology.

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial

Jennifer G. Robinson, Alex A. Knopman, D. Rujescu, 2021, The Lancet Neurology.

Non-coding variability at the APOE locus contributes to the Alzheimer’s risk

Sterling C. Johnson, Keith A. Johnson, Raymond Scott Turner, 2019, Nature Communications.

P2–412: MPC–7869 (R–flurbiprofen), a selective Aβ42–lowering agent, delays time to clinically significant psychiatric events in Alzheimer's disease (AD): Analysis from a 12–month phase 2 trial

S. Hendrix, J. Mintzer, G. Wilcock, 2006 .

Four distinct trajectories of tau deposition identified in Alzheimer’s disease

Sterling C. Johnson, John X. Morris, Keith A. Johnson, 2021, Nature Medicine.

Mining Outcome-relevant Brain Imaging Genetic Associations via Three-way Sparse Canonical Correlation Analysis in Alzheimer’s Disease

Michael W. Weiner, Robert C. Green, Shannon L. Risacher, 2017, Scientific Reports.

Predicting Alzheimer’s disease progression using multi-modal deep learning approach

Keith A. Johnson, Sherye A. Sirrel, Alice D. Brown, 2019, Scientific Reports.

Dissociation of tau pathology and neuronal hypometabolism within the ATN framework of Alzheimer’s disease

Sterling C. Johnson, Keith A. Johnson, Raymond Scott Turner, 2022, Nature Communications.

Disease-modifying therapies in Alzheimer’s disease ⁎ ⁎ EDITOR’S NOTE: The Journal intended to include this article in the January 2008 supplement, “Leon Thal Symposium on Prevention of Dementia.”

J. Cummings, S. Salloway, M. Weiner, 2008, Alzheimer's & Dementia.

Longitudinal measurement and hierarchical classification framework for the prediction of Alzheimer’s disease

Andrew J. Saykin, Arthur W. Toga, Qianjin Feng, 2017, Scientific Reports.

Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts

Keith A. Johnson, Raymond Scott Turner, Sherye A. Sirrel, 2016, Scientific Reports.

Apolipoprotein E and gray matter volume loss in patients with mild cognitive impairment and Alzheimer disease.

Zoran Rumboldt, Jacobo E. Mintzer, Maria Vittoria Spampinato, 2011, Radiology.

The many faces of psychosis in the elderly

J. Mintzer, Jessica Broadway, 2007, Current opinion in psychiatry.

Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: results of a double-blind, placebo-controlled trial

L. Schneider, P. Tariot, J. Mintzer, 2001 .

Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease

Keith A. Johnson, Charles D. Smith, Sherye A. Sirrel, 2020, Nature Communications.

Staging tau pathology with tau PET in Alzheimer’s disease: a longitudinal study

Nick C Fox, Keith A. Johnson, Raymond Scott Turner, 2021, Translational Psychiatry.

KL-VS heterozygosity is associated with lower amyloid-dependent tau accumulation and memory impairment in Alzheimer’s disease

Keith A. Johnson, Raymond Scott Turner, Sherye A. Sirrel, 2021, Nature Communications.

Neurobiologic Rationale for Treatment of Apathy in Alzheimer’s Disease With Methylphenidate

A. Levey, A. Arnsten, N. Herrmann, 2020, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo-controlled trial

Sarah A. Chau, N. Herrmann, J. Mintzer, 2013, International Psychogeriatrics.

Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial.

N. Herrmann, J. Mintzer, K. Lanctôt, 2013, The Journal of clinical psychiatry.

Sertraline for the treatment of depression in Alzheimer disease.

L. Schneider, C. Lyketsos, P. Rabins, 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

A retrospective, population-based cohort study of driving under the influence, Alzheimer’s disease diagnosis, and survival

J. Mintzer, G. Rahimi, Dennis Orwat, 2018, International Psychogeriatrics.

Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer’s disease (MCI and dementia) in primary care: a review and synthesis

G. Small, A. Atri, J. Susman, 2021, Journal of internal medicine.

Learning from the Failure of Alzheimer's disease clinical trials: Is the amyloid hypothesis discredited?

N. Greig, A. Granholm, J. Mintzer, 2012 .

Vitamin E and memantine in Alzheimer's disease: Clinical trial methods and baseline data

G. Schellenberg, J. McCarten, M. Sano, 2014, Alzheimer's & Dementia.

A Novel Joint Brain Network Analysis Using Longitudinal Alzheimer’s Disease Data

Norbert Schuff, Michael W. Weiner, Andrew J. Saykin, 2019, Scientific Reports.

Lifestyle Choices and Brain Health

J. Mintzer, L. Chura, S. Lock, 2019, Front. Med..

Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses.

J. Mintzer, R. Mcquade, L. Tune, 2007, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Donepezil in vascular dementia

R. Doody, R. Helme, A. Kertesz, 2003, Neurology.

The trend of disruption in the functional brain network topology of Alzheimer’s disease

Sterling C. Johnson, Keith A. Johnson, Raymond Scott Turner, 2021, Scientific Reports.

Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.

L. Schneider, P. Tariot, I. Katz, 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Attentional functioning in patients with posttraumatic stress disorder: a preliminary study

T. Turner, J. Mintzer, M. Horner, 2013, CNS Spectrums.

Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images

Adrian Preda, Evan Fletcher, Godfrey Pearlson, 2018, Scientific Reports.

Glucose metabolism patterns: A potential index to characterize brain ageing and predict high conversion risk into cognitive impairment

Keith A. Johnson, Raymond Scott Turner, Sherye A. Sirrel, 2022, GeroScience.

Regional Amyloid-β Load and White Matter Abnormalities Contribute to Hypometabolism in Alzheimer’s Dementia

Sterling C. Johnson, Keith A. Johnson, Charles D. Smith, 2018, Molecular Neurobiology.

Preliminary examination of progression of Alzheimer's disease in a rural Southern African American cohort.

N. Carlozzi, J. Mintzer, D. Bachman, 2007, Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists.

Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies

R. Sperling, P. Aisen, R. Raman, 2021, Sleep advances : a journal of the Sleep Research Society.

Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference

Nick C Fox, Keith A. Johnson, Raymond Scott Turner, 2017, Nature Communications.

The Dementias: Policy and Management

J. Mintzer, 1987 .

Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer’s Disease

David M. Shade, J. Yesavage, L. Schneider, 2018, American journal of Alzheimer's disease and other dementias.

Deep learning-based polygenic risk analysis for Alzheimer’s disease prediction

Keith A. Johnson, Raymond Scott Turner, Sherye A. Sirrel, 2023, Communications Medicine.

Comparison of Rapidly Acting Intramuscular Olanzapine, Lorazepam, and Placebo: A Double-blind, Randomized Study in Acutely Agitated Patients with Dementia

Charles M Beasley, J. Mintzer, B. Jones, 2002, Neuropsychopharmacology.

Relapse risk after discontinuation of risperidone in Alzheimer's disease.

D. Devanand, G. Pelton, H. Andrews, 2012, The New England journal of medicine.

Effect of psychotropic drugs on development of diabetes mellitus in patients with Alzheimer’s disease

David M. Shade, J. Yesavage, L. Schneider, 2015, Alzheimer's & Dementia.

Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics

Norbert Schuff, Michael W. Weiner, Robert C. Green, 2019, Scientific Reports.

Plasma phosphorylated-tau181 as a predictive biomarker for Alzheimer’s amyloid, tau and FDG PET status

Sterling C. Johnson, Nick C Fox, Keith A. Johnson, 2021, Translational Psychiatry.

Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial

David M. Shade, J. Yesavage, L. Schneider, 2015, International Psychogeriatrics.

A new approach for the management of acute psychiatric disorders in elderly demented patients.

J. Mintzer, D. Bachman, L. Lewis, 1994, Journal of the South Carolina Medical Association.

Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients

Keith A. Johnson, Raymond Scott Turner, Charles D. Smith, 2022, Nature Aging.

A Double-blind Placebo-controlled Case Study of the Use of Donepezil to Improve Cognition in a Schizoaffective Disorder Patient: Functional MRI Correlates.

C L DeVane, Z. Nahas, M. George, 2001, Neurocase.

Cost consequence analysis of Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).

David M. Shade, N. Herrmann, C. V. van Dyck, 2023, International psychogeriatrics.

Fluoroquinolone inhibition of clozapine metabolism.

J. Mintzer, J. Markowitz, C. DeVane, 1997, The American journal of psychiatry.

A Randomized, Double‐Blind, Placebo‐Controlled Study of the Efficacy and Safety of Donepezil in Patients with Alzheimer's Disease in the Nursing Home Setting

P. Tariot, I. Katz, J. Cummings, 2001, Journal of the American Geriatrics Society.

SIADH associated with fluoxetine and sertraline therapy.

J. Mintzer, J. Markowitz, C. Jackson, 1995, The American journal of psychiatry.

Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.

David M. Shade, J. Yesavage, L. Schneider, 2015, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes.

L. Schneider, C. Lyketsos, P. Rabins, 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Design of Depression in Alzheimer's Disease Study-2.

L. Schneider, C. Lyketsos, I. Katz, 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Daughters caregiving for hispanic and non-hispanic alzheimer patients: Does ethnicity make a difference?

J. Mintzer, C. Eisdorfer, D. Loewenstein, 1992, Community Mental Health Journal.

Dementia in the incarcerated population: a retrospective study using the South Carolina Alzheimer's disease registry, USA.

J. Mintzer, Jennifer Bronson, Glaucia Salgado, 2023, International journal of prisoner health.

Cascaded Multi-view Canonical Correlation (CaMCCo) for Early Diagnosis of Alzheimer’s Disease via Fusion of Clinical, Imaging and Omic Features

Adrian Preda, Evan Fletcher, Charles DeCarli, 2017, Scientific Reports.

Effectiveness of a continuum of care using brief and partial hospitalization for agitated dementia patients.

J. Mintzer, M. Saladin, D. Bachman, 1997, Psychiatric Services.

Brain multiplexes reveal morphological connectional biomarkers fingerprinting late brain dementia states

Islem Rekik, Mohamed Ali Mahjoub, Keith A. Johnson, 2018, Scientific Reports.

Introduction: the clinical impact of agitation in various psychiatric disorders: management consensus and controversies.

J. Mintzer, 2006, The Journal of clinical psychiatry.

Identifying Abnormal Network Alterations Common to Traumatic Brain Injury and Alzheimer's Disease Patients Using Functional Connectome Data

Jane E. Joseph, Xun Zhu, Guorong Wu, 2015, MLMI.

ZOLPIDEM‐INDUCED PSYCHOSIS IN AN OLDER WOMAN

J. Mintzer, M. Neville, Janet K. Pitner, 1997, Journal of the American Geriatrics Society.

Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition.

M. Sano, D. Gerritsen, J. Mintzer, 2023, International psychogeriatrics.

The BIN1 rs744373 SNP is associated with increased tau-PET levels and impaired memory

Keith A. Johnson, Raymond Scott Turner, Sherye A. Sirrel, 2019, Nature Communications.

The Apathy in Dementia Methylphenidate Trial 2 (ADMET 2): study protocol for a randomized controlled trial

Raymond Scott Turner, Susie A. Sami, David M. Shade, 2018, Trials.

Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET).

N. Herrmann, J. Mintzer, K. Lanctôt, 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.

David M. Shade, H. Kraemer, J. Yesavage, 2016, Journal of psychiatric research.

Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: a randomized, controlled trial.

L. Schneider, P. Tariot, L. Thal, 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Leukocyte surface biomarkers implicate deficits of innate immunity in sporadic Alzheimer's disease

C. Rowe, J. Pickering, C. Masters, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease

L. Thal, J. Mintzer, S. Targum, 1999, Neurology.

Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis

J. Mintzer, A. Breier, V. Sutton, 2001, International journal of geriatric psychiatry.

R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.

David M. Shade, J. Yesavage, L. Schneider, 2016, British journal of clinical pharmacology.

Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.

David M. Shade, J. Yesavage, L. Schneider, 2016, The American journal of psychiatry.

Citalopram for agitation in Alzheimer’s disease: Design and methods

J. Yesavage, L. Schneider, C. Lyketsos, 2012, Alzheimer's & Dementia.

EffectofCitalopramonAgitationinAlzheimerDisease The CitAD Randomized Clinical Trial

David M. Shade, J. Yesavage, L. Schneider, 2014 .

Reduction and Prevention of Agitation in Patients with Neurocognitive Disorders: An International Psychogeriatric Association Consensus Algorithm

M. Sano, D. Gerritsen, J. Mintzer, 2022, International psychogeriatrics.

A randomized, placebo‐controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil

K. Krishnan, S. Finkel, J. Mintzer, 2004, International journal of geriatric psychiatry.

Safety and benefits of distance‐adjusted prefrontal transcranial magnetic stimulation in depressed patients 55–75 years of age: A pilot study

Xingbao Li, Jacobo Mintzer, Daryl E Bohning, 2004, Depression and anxiety.

Do treatment effects vary among differing baseline depression criteria in depression in Alzheimer's disease study ± 2 (DIADS‐2)?

L. Schneider, C. Lyketsos, P. Rabins, 2011, International journal of geriatric psychiatry.

Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics

Keith A. Johnson, Michael W. Paul Ronald Clifford R. Andrew J. William John Weiner Aisen Petersen Jack Saykin Jagust , Sherye A. Sirrel, 2019, Scientific Reports.

Cognitive outcomes after sertaline treatment in patients with depression of Alzheimer disease.

L. Schneider, C. Lyketsos, P. Rabins, 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Social Isolation and Social Support: An Applied Perspective

J. Mintzer, J. Lubben, R. Rubinstein, 1994 .

Citalopram for the Treatment of Agitation in Alzheimer Dementia

David M. Shade, J. Yesavage, L. Schneider, 2016, Journal of geriatric psychiatry and neurology.

Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology

György J. Simon, David T. Jones, Keith A. Johnson, 2020, Scientific Reports.

Combination pharmacotherapy in Alzheimer's disease

J. Mintzer, W. Faison, D. Armstrong, 2003, Dialogues in clinical neuroscience.

Perspective from Clinical Research: Ethical Issues in Alzheimer's Disease Research

J. Mintzer, 2018, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.

Using risperidone for Alzheimer's dementia-associated psychosis

J. Mintzer, K. Lukacs, Renee P. Meyer, 2008 .

What Are the Challenges Faced by Psychiatrists in the Management of Alzheimer's Disease?

J. Mintzer, 2004, CNS Spectrums.

Higher CSF sTNFR1-related proteins associate with better prognosis in very early Alzheimer’s disease

Sterling C. Johnson, Keith A. Johnson, Raymond Scott Turner, 2021, Nature Communications.

Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.

Xin Yu, Jacobo Mintzer, K. Krishnan, 2003, The American journal of psychiatry.

Principal components analysis of agitation outcomes in Alzheimer's disease.

Jeannie-Marie S. Leoutsakos, David M. Shade, J. Yesavage, 2016, Journal of psychiatric research.

Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial

Curtis L. Meinert, Bruce G. Pollock, Daniel Weintraub, 2014, Alzheimer's & Dementia.

Depression in Alzheimer’s disease: consequence or contributing factor?

J. Mintzer, C. O'Neill, 2011, Expert review of neurotherapeutics.

Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer's Disease Study 2.

L. Schneider, C. Lyketsos, P. Rabins, 2014, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design.

D. Devanand, G. Pelton, H. Andrews, 2012, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Risperidone in Dementia

J. Mintzer, S. Madhusoodanan, R. Brenner, 2000 .

A Markov Model of the Cost Effectiveness of Olanzapine Treatment for Agitation and Psychosis in Alzheimer’s Disease

J. Mintzer, K. Simpson, P. Nietert, 2008, Clinical drug investigation.

A telescope GWAS analysis strategy, based on SNPs-genes-pathways ensamble and on multivariate algorithms, to characterize late onset Alzheimer’s disease

Sterling C. Johnson, Keith A. Johnson, Sherye A. Sirrel, 2020, Scientific Reports.

Notably higher rates of vascular risk factors and dementia among African Americans in South Carolina: opportunities for public health intervention.

S. Laditka, J. Mintzer, J. Laditka, 2008, Journal of the South Carolina Medical Association.

Heterogeneity of response to methylphenidate in apathetic patients in the ADMET 2 Trial

A. Levey, N. Herrmann, C. V. van Dyck, 2022, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

Elderly Veterans with Combat-Related Posttraumatic Stress Disorder in Specialty Care

J. Elhai, J. Mintzer, B. Frueh, 2004, The Journal of nervous and mental disease.

Establishment of a Predominantly African-American Cohort for the Study of Alzheimer’s Disease

J. Mintzer, V. Hirth, D. Bachman, 2009, Dementia and Geriatric Cognitive Disorders.

Behavioral and psychological signs and symptoms of dementia: a practicing psychiatrist's viewpoint.

J. Mintzer, D. Mirski, K. Hoernig, 2000 .

Behavioral and psychologic symptoms of dementia: How does this conceptualization help us?

J. Mintzer, R. Rubey, 2005 .

ects of a flexible galantamine dose in Alzheimer ’ s disease : a randomised , controlled trial

J. Mintzer, K. Rockwood, D. Wilkinson, 2001 .

E V ects of a flexible galantamine dose in Alzheimer ’ s disease : a randomised , controlled trial

J. Mintzer, K. Rockwood, D. Wilkinson, 2001 .

EVects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial

J. Mintzer, K. Rockwood, L. Truyen, 2001 .

Consensus provisional definition of agitation in cognitive disorders

C. Lyketsos, M. Sano, J. Cummings, 2019, Definitions.

Alzheimer's Disease in the Family Practice Setting: Assessment of a Screening Tool.

J. Mintzer, R. Carter, Y. Palesch, 2004, Primary care companion to the Journal of clinical psychiatry.

ß-Blockers and Cognitive Performance in Older Patients

J. Mintzer, 1989 .

Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer's Disease using structural MR and FDG-PET images

Sterling C. Johnson, Mirza Faisal Beg, Karteek Popuri, 2017, ArXiv.

18F-florbetapir Positron Emission Tomography-determined Cerebral β-Amyloid Deposition and Neurocognitive Performance after Cardiac Surgery.

Sterling C. Johnson, David T. Jones, Keith A. Johnson, 2018, Anesthesiology.

Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease

Sterling C. Johnson, Keith A. Johnson, Charles D. Smith, 2020, Nature Communications.

Psychometric Properties of Apathy Scales in Dementia: A Systematic Review.

N. Herrmann, J. Mintzer, K. Lanctôt, 2018, Journal of Alzheimer's disease : JAD.

Challenges and Opportunities with Causal Discovery Algorithms: Application to Alzheimer’s Pathophysiology

Norbert Schuff, Michael W. Weiner, Andrew J. Saykin, 2020, Scientific Reports.

Effects of methylphenidate on neuropsychiatric symptoms in Alzheimer's disease: Evidence from the ADMET 2 study

Susie A. Sami, David M. Shade, N. Herrmann, 2023, Alzheimer's & dementia.

FAM222A encodes a protein which accumulates in plaques in Alzheimer’s disease

David T. Jones, Keith A. Johnson, Charles D. Smith, 2020, Nature Communications.

Genome-wide association analysis of hippocampal volume identifies enrichment of neurogenesis-related pathways

John X. Morris, Keith A. Johnson, Raymond Scott Turner, 2019, Scientific Reports.

GenEpi: gene-based epistasis discovery using machine learning

Michael W. Weiner, Yen-Jen Oyang, Arthur W. Toga, 2020, BMC Bioinformatics.

A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone

J. Mintzer, J. Mullen, D. Sweitzer, 2004, Current medical research and opinion.

A blood-based signature of cerebrospinal fluid Aβ1–42 status

John X. Morris, Keith A. Johnson, Raymond Scott Turner, 2019, Scientific Reports.

Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease

Keith A. Johnson, Raymond Scott Turner, Sherye A. Sirrel, 2018, Scientific Reports.

Dissection of the polygenic architecture of neuronal Aβ production using a large sample of individual iPSC lines derived from Alzheimer’s disease patients

Keith A. Johnson, Raymond Scott Turner, Charles D. Smith, 2022, Nature Aging.

Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts

Sterling C. Johnson, Raymond Scott Turner, Sherye A. Sirrel, 2016, Scientific Reports.

Prognostic relevance of gait-related cognitive functions for dementia conversion in amnestic mild cognitive impairment

John X. Morris, Keith A. Johnson, Raymond Scott Turner, 2023, BMC Geriatrics.

A blood-based signature of cerebrospinal fluid Aβ1–42 status

Raymond Scott Turner, Sherye A. Sirrel, Alice D. Brown, 2019, Scientific Reports.

Behavioral Intensive Care Unit (BICU): a new concept in the management of acute agitated behavior in elderly demented patients.

J. Mintzer, D. Bachman, L. Lewis, 1993, The Gerontologist.

Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE

Sterling C. Johnson, Sherye A. Sirrel, Alice D. Brown, 2015, Nature Communications.

The search for better noncholinergic treatment options for Alzheimer's disease.

J. Mintzer, 2003, The Journal of clinical psychiatry.

The prevalence of dementia: The confusion of numbers

J. Mintzer, N. A. Persily, L. Blume, 1992 .

Higher CSF sTREM2 attenuates ApoE4-related risk for cognitive decline and neurodegeneration

Sterling C. Johnson, Raymond Scott Turner, Alice D. Brown, 2020, Molecular neurodegeneration.

Fenfluramine challenge test as a marker of serotonin activity in patients with alzheimer’s dementia and agitation

J. Mintzer, O. Brawman‐Mintzer, R. Unger, 1998, Biological Psychiatry.

Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm

Corinne E. Fischer, M. Sano, D. Gerritsen, 2023, International Psychogeriatrics.